LC-Plasma for Preventing URTIs and Reducing Symptoms

Inclusion Criteria:

• Adults aged 18-60 years living in Australia

• Individuals with a history of recurrent upper respiratory tract infections

• Able to provide informed consent

• Generally healthy

• Agree to not participate in another clinical trial while enrolled in this trial

• Agree to maintain their usual daily activities without significant changes. Thisincludes not changing their current diet or stopping/starting a new exercise regimenduring entire study period

• Agree not to travel internationally for over 1 month in a single trip during theintervention period (baseline to study completion).

• Females of childbearing potential must a prescribed form of birth control

Exclusion Criteria:

• Serious illness e.g., liver disease, kidney disease, heart disease, mood disorders,neurological disorders such as multiple sclerosis.

• Unstable illness e.g., changing medication/treatment.

• BMI <18.5, >30

• Current malignancy (excluding Basal Cell Carcinoma) or chemotherapy or radiotherapytreatment for malignancy within the previous 2 years.

• Individuals with chronic respiratory conditions (e.g., asthma, chronic obstructivepulmonary disease).

• Has current symptoms of an acute sickness.

• Active smokers, nicotine use or drug (prescription or illegal substances) abuse

• Current alcohol use (>14 alcoholic drinks week)

• Allergic to any of the ingredients in the active or placebo formula

• Pregnant or lactating woman

• People medically prescribed medications within the last month that would affect theimmune and/or the inflammatory response excluding topical steroid use.

• Participants who are currently participating in any other clinical trial or who haveparticipated in any other clinical trial during the past 1 month

• Participants with cognitive damage

• Participants with seasonal allergic rhinitis

• Regular use of antihistamines

• Individuals deemed unsuitable for participation by the Principal Investigator (PI)of this study.